Faricimab improves visual acuity, reduces central subfield thickness

October 04, 2022

3 minute watch


Source/Disclosures

Source:

LimJI. Year 2 anti-VEGF/anti-Ang2 results for diabetic macular edema and neovascular AMD. Presented at the meeting of the American Academy of Ophthalmology; Sept. 30-Oct. 3, 2022; Chicago.


Disclosures: Lim is a consultant for Genentech and Regeneron.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

CHICAGO – In this Healio video perspective of the AAO meeting, Jennifer I. Lim, MARYLAND, discusses Year 1 and Year 2 data for faricimab for the treatment of age-related macular degeneration and diabetic macular edema.

According to Lim, faricimab treatment resulted in improvements in visual acuity and reductions in central subfield thickness and demonstrated prolonged durability.

Comments are closed.